Advertisement

BMC Medical Genetics

, 20:29 | Cite as

TNFSF15 promoter polymorphisms increase the susceptibility to small cell lung cancer: a case-control study

  • Hui Gao
  • Zeren Niu
  • Zhi Zhang
  • Hongjiao Wu
  • Yuning Xie
  • Zhenbang Yang
  • Ang Li
  • Zhenxian Jia
  • Xuemei ZhangEmail author
Open Access
Research article
First Online:
  • 60 Downloads
Part of the following topical collections:
  1. Genetic epidemiology and genetic associations

Abstract

Background

Tumor necrosis factor superfamily member 15 (TNFSF15) is closely related to tumorigenesis and development. This study aimed to investigate the correlations between TNFSF15 polymorphisms and genetic susceptibility to lung cancer.

Methods

This case-control study included 209 small cell lung cancer patients (SCLC), 340 non- small cell lung cancer patients (NSCLC) and 460 health controls. TNFSF15–638 A > G and − 358 T > C polymorphisms were genotyped by polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP) analysis. Odds ratio (OR) and 95% confidence interval (95% CI) were estimated by unconditional logistic regression.

Results

Our results showed that subjects carrying the TNFSF15–638GG genotype or -358CC genotype were more likely to develop SCLC (−638GG, OR = 1.84, 95%CI = 1.13–2.99; -358CC, OR = 2.44, 95%CI = 1.46–4.06), but not NSCLC (P > 0.05). In stratified analysis, −638GG genotype was related to SCLC among males (OR = 1.95, 95%CI = 1.09–3.45, P = 0.023) and older patients (OR = 2.93, 95%CI = 1.44–8.68, P = 0.006). However, -358CC genotype was associated with SCLC among females (OR = 8.42, 95%CI = 2.22–31.89, P = 0.002) and older subjects with OR (95%CI) of 11.04 (3.57–34.15) (P < 0.001). Moreover, TNFSF15 -358CC was linked with a higher risk of SCLC among non-smokers (OR = 2.54, 95%CI = 1.20–5.35, P = 0.015) but not among smokers (OR = 1.88, 95%CI = 0.92–3.84, P = 0.086).

Conclusion

These findings highlight the importance of TNFSF15 polymorphisms in the development of SCLC.

Keywords

TNFSF15 Lung cancer Single nucleotide polymorphism Cancer susceptibility 

Abbreviations

NSCLC

non-small cell lung cancer

SCLC

small cell lung cancer

TNFSF15

Tumor necrosis factor superfamily member 15

Background

Lung cancer is one of the most common malignant tumors worldwide and the first leading cause of cancer-related mortality in China [1, 2]. According to World Health Organization, lung cancer is divided into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which NSCLC accounts for almost 85% of lung cancer cases [3]. Epidemiological studies have identified several risk factors for lung cancer, such as tobacco smoking, atmospheric pollution and occupational environment challenge [4]. However, many individuals who have been exposed to these risk factors do not get lung cancer during lifetime, so genetic factor is likely play an important role.

The initiation and progression of cancer are closely linked to inflammation and angiogenesis [5, 6]. As one of potent mediators of inflammation, the tumor necrosis factor (TNF) family plays an important role in the process of immunoregulation and further contributes to cancer development [7]. Tumor necrosis factor superfamily 15 (TNFSF15), also known as vascular endothelial growth inhibitor (VEGI), belongs to the TNF ligand family, which negatively regulates angiogenesis [8]. By stimulating T cell, TNFSF15 is involved in the modulation of inflammation [9, 10]. Studies have shown that over-expression of TNFSF15 inhibits tumor growth in various cancers whereas reduced expression of TNFSF15 is associated with poor prognosis in cancer patients [11, 12, 13, 14, 15].

Single nucleotide polymorphisms (SNPs) in regulatory region of a gene can influence the gene expression and further contribute to the development of various cancers [16, 17, 18, 19]. In our previous study, we identified two SNPs (−638A > G and -358 T > C) in the TNFSF15 promoter by direct sequencing, and found that -358 T > C variant changed the transcriptional activity of TNFSF15 and was significantly associated with the susceptibility to gastric adenocarcinoma [20]. In the present study, we tested if these two variants in the TNFSF15 promoter region contributed to the risk of developing lung cancer by performing a case-control study in a Chinese population.

Methods

Study population

This case-control study consisted of 209 SCLC patients, 340 NSCLC patients and 460 healthy controls (Table 1). The 549 cases were collected from Tangshan Gongren Hospital and Tangshan Renmin Hospital affiliated to North China University of Science and Technology in China from 2012 to 2016. None of the patients were treated with any radiotherapy or chemotherapy before blood sampling. All subjects were unrelated ethnic Han Chinese. Control individuals without a history of any cancer were recruited from the same region and frequency-matched to cases according to gender and age. This study was approved by Institutional Review Board of North China University of Science and Technology, and written informed consents were obtained from all participants of their own free will.
Table 1

Frequency distribution of select characteristics

Variables

NSCLC

SCLC

Case (n = 340)

Controls(n = 460)

P value*

Case (n = 209)

Controls(n = 460)

P value*

No

(%)

No

(%)

 

No

(%)

No

(%)

 

Gender

 

0.301

  

0.862

 Male

237

69.7

336

73.0

 

154

73.7

336

73.0

 

 Female

103

30.3

124

27.0

 

55

26.3

124

27.0

 

Age

 

0.139

  

0.151

 <60

187

55.0

277

60.2

 

138

66.0

277

60.2

 

  ≥ 60

153

45.0

183

39.8

 

71

34.0

183

39.8

 

Range

27–84

18–84

 

30–92

18–84

 

Median

58

56.2

 

55

56.2

 

Smoking status

 

0.252

  

0.431

 Non-smoker

187

55.0

233

50.7

 

99

47.8

233

50.7

 

 Smoker

153

45.0

227

49.3

 

110

52.2

227

49.3

 

Pack year of smoking

 

< 0.001

  

< 0.001

 <30

59

38.6

153

67.4

 

37

33.7

153

67.4

 

  ≥ 30

94

61.4

74

32.6

 

73

66.4

74

32.6

 

*Two-sided χ2 test

TNFSF15 genotyping

Genomic DNA was extracted from peripheral blood from all participants using TIANamp Blood DNA Kit (TIANGEN, Beijing, China), according to the manufacturer’s instructions. PCR-restriction fragment length polymorphism (PCR-RFLP) analysis were applied for TNFSF15 genotyping. The PCR primer pairs for −638A > G (rs7848647) were 5′- AGT CAC CTC GAT CTG TGG CCTC-3′ and 5′-AAT CAC GGC TTG GAG TTG TAA CCTC-3′. The target DNA fragment containing − 358 T > C (rs6478109) was amplified with primer pairs, − 358 -PF (5′-AAA TGT GAT TTC CGT TTC CCCA-3′) and − 358 -PR (5′- AAT ATA CCT GTT CCC TGC ACTG -3′). Briefly, PCR was performed using 6 μL reaction mixture containing 10 ng DNA, 0.1 μM each primer, and 1 × Taq PCR StarMix with loading dye (Genstar, Beijing, China).The PCR thermal cycling condition consists of an initial denaturation step at 94 °C for 3 min, followed by 30 cycles of 94 °C for 40 s, 58 °C for 30 s and 72 °C for 15 s, and then a final extension step at 72 °C for 3 min. PCR products for TNFSF15–638A > G (114 bp) and -358 T > C (123 bp) were digested by Rsa I and Bcc I (New England BioLabs, Inc., Beverly, USA) and separated on 3% agarose gel. The genotypes revealed by PCR-RFLP were further confirmed by DNA sequencing (Fig. 1). To ensure the quality control, approximately10% of the samples were randomly selected for re-genotyping and all results were in 100% concordance.
Fig. 1

Sequence analyses of the TNFSF15 promoter region reveal 2 SNPs located at nucleotides a − 638 A > G and b − 358 T > C. The arrows localize the base changes at the nucleotide positions

Statistical analysis

Quanto program was used to calculate the power of the sample size for this case-control study. The power estimation was performed, which indicated that our sample size is sufficient for the case-control study. Differences of basic characteristics in cases and control subjects were compared using the χ2 test. Pearson goodness-of-fit χ2 test was performed to test whether the distribution of genotypes in the control group was in accordance with Hardy-Weinberg Equilibrium (HWE). Odd ratios (ORs) and 95% Confidence interval (CI) were calculated by unconditional logistic regression model to evaluate the association of TNFSF15 genetic variations with the susceptibility to lung cancer. The smoking status of pack-years was determined as an indicator of the cumulative cigarette dose level (pack-years cigarettes per day/20 × years smoked). Light and heavy smokers were categorized by using 30 as the cut-off point [21]. Older and younger subjects were sub-grouped by using 60 as the cut-off point (https://www.who.int). All statistical calculations were performed using SPSS version 23.0 (SPSS Inc., Chicago, IL).

Results

Demographic and clinical characteristics of lung cancer cases and controls

Demographic and clinical characteristics of lung cancer cases and controls are shown in Table 1. There was no significant difference in gender, age and smoking status between NSCLC or SCLC cases and healthy controls (P > 0.05). In terms of the amount of smoking, the significant difference was showed between lung cancer group and control group (P < 0.001 for NSCLC and P < 0.001 for SCLC). The proportion of heavy smokers in SCLC and NSCLC patients (66.4 and 61.4%) was significantly higher than that in healthy controls (32.6%).

Association of TNFSF15 variants with the risk of lung cancer

Tables 2 and  3 present the genotypes of TNFSF15–638A > G and -358 T > C variants in lung cancer patients and controls. Genotype distributions of TNFSF15–638A > G and -358 T > C in controls were conformed to be in the Hardy-Weinberg equilibrium (HWE) (P = 0.32 and P = 0.78, respectively). We used unconditional logistic regression to assess the association of TNFSF15 SNPs with the risk of lung cancer. For the TNFSF15–638A > G polymorphism, we found that GG genotype carriers had a significantly elevated risk for developing SCLC (OR = 1.84, 95%CI = 1.13–2.99), but not for developing NSCLC (OR = 1.11, 95%CI = 0.74–1.67), in comparison to those with AA genotype. For the TNFSF15 -358 T > C variant, our data showed that CC genotype and CT genotype were associated with a higher risk of SCLC (OR = 2.44, 95%CI = 1.46–4.06; OR = 2.00, 95%CI = 1.26–3.19) as compared to TT genotype. However, we did not find that the TNFSF15 -358 T > C polymorphism was associated with the susceptibility to NSCLC with an OR (95% CI) of 1.45 (0.96–2.11) in CT carriers and an OR (95% CI) of 1.24 (0.86–1.76) in CC carriers, respectively.
Table 2

Genotype frequencies of TNFSF15 polymorphisms and their association with SCLC

Genotype

Patients(n = 209)

Controls(n = 460)

OR (95%CI)a

P value

No

(%)

No

(%)

  

-638 A > G

 AA

39

18.7

122

26.5

  

 AG

112

53.5

240

52.2

1.46(0.95–2.23)

0.084

 GG

58

27.8

98

21.3

1.84(1.13–2.99)

0.014

-358 T > C

 TT

29

13.9

116

25.2

  

 CT

114

54.5

233

50.7

2.00(1.26–3.19)

0.004

 CC

66

31.6

111

24.1

2.44(1.46–4.06)

0.001

aAdjusted for age, gender, and smoking status

Table 3

Genotype frequencies of TNFSF15 polymorphisms and their association with NSCLC

Genotype

Patients(n = 340)

Controls(n = 460)

OR (95%CI)a

P value

No

(%)

No

(%)

  

-638 A > G

 AA

90

26.5

122

26.5

  

 AG

171

50.3

240

52.2

0.97(0.69–1.36)

0.867

 GG

79

23.2

98

21.3

1.11(0.74–1.67)

0.605

-358 T > C

 TT

71

20.9

116

25.2

  

 CT

173

50.9

233

50.7

1.24(0.86–1.76)

0.248

 CC

96

28.2

111

24.1

1.45(0.96–2.11)

0.074

aAdjusted for age, gender, and smoking status

Stratification analysis of the TNFSF15 polymorphism and the risk of SCLC

To evaluate the effect of smoking status and non-modifiable risk factors (age and gender) on the association of TNFSF15–638A > G with the risk of SCLC, we performed stratification analysis (Table 4). When stratified by gender, the TNFSF15–638GG genotype was associated with an increased risk of SCLC among males compared with the AA genotype (OR = 1.95, 95%CI = 1.09–3.45, P = 0.023), but not among females. Our data also showed that the risk of SCLC was associated with the −638GG genotype among older subjects with an OR (95% CI) of 2.93 (1.44–8.68), but not among younger subjects with an OR (95% CI) of 1.28 (0.71–2.34). However, no effect of the TNFSF15–638A > G variation on the risk of SCLC was found in stratified analysis based on smoking status.
Table 4

Association of TNFSF15–638A > G polymorphism with SCLC risk stratified by selected variables

Variables

Genotypes (Cases/Controls)

GG/AA model

OR (95% CI)

P value

GG

AG

AA

Gender

 Male

42/72

84/170

28/94

1.95(1.09–3.45)

0.023

 Female

16/26

28/70

11/28

1.41(0.54–3.70)

0.483

Age

 <60

37/62

71/149

30/66

1.28(0.71–2.34)

0.407

  ≥ 60

21/36

41/91

9/56

2.93(1.44–8.68)

0.006

Smoking status

 Non-smoker

28/49

53/124

18/60

1.79(0.88–3.65)

0.107

 Smoker

30/49

59/116

21/62

1.70(0.86–3.38)

0.130

We then performed stratification analysis to evaluate the association of TNFSF15 -358 T > C genotypes with SCLC (Table 5). Compared with the TT genotype, the CC genotype was associated with a higher risk of SCLC among females (OR = 8.42, 95%CI = 2.22–31.89, P = 0.002), but not among males. Age stratification analysis showed that there was a correlation between the CC genotype and the risk of SCLC (OR = 11.04, 95%CI = 3.57–34.15, P = 0.000) among elders when compared to TT carriers, but not among youngers. In addition, the CC genotype increased the risk of lung cancer among non-smokers (OR = 2.54, 95%CI = 1.20–5.35, P = 0.015) compared with the TT genotype.
Table 5

Association of TNFSF15 -358 T > C polymorphism with SCLC risk stratified by selected variables

Variables

Genotypes (Cases/Controls)

CC/TT model

OR (95% CI)

P value

CC

CT

TT

Gender

 Male

42/85

86/164

26/87

1.66(0.93–2.95)

0.086

 Female

24/26

28/69

3/29

8.42(2.22–31.89)

0.002

Age

 <60

35/71

78/146

25/60

1.15(0.62–2.15)

0.653

  ≥ 60

31/40

36/87

4/56

11.04(3.57–34.15)

< 0.001

Smoking status

 Non-smoker

36/55

51/123

12/55

2.54(1.20–5.35)

0.015

 Smoker

30/56

63/110

17/61

1.88(0.92–3.84)

0.086

Discussion

Small-cell lung cancer (SCLC) is a deadly tumor with poor prognosis, which originates from high-grade malignant neuroendocrine cells [22]. Although sensitive to chemotherapy and radiotherapy, SCLC typically recurs rapidly after primary treatment and the five-year survival is only 6% after diagnosis [23]. Platinum-etoposide doublet has been officially approved for clinical use against SCLC [23]; however, few improvement has been made in SCLC treatment in past several years. Since SCLC is known as a stubborn cancer, there is an urgent need for the identification of biomarkers that can act as a potential therapeutic target in SCLC.

TNF superfamily members play an important role in cell proliferation, differentiation and apoptosis and are used for clinical treatment, or in clinical trials [24, 25]. TNFSF15, a member of TNF superfamily, is likely to inhibit the growth of tumors by suppressing neovascularization. TNFSF15 inhibits the proliferation of vascular endothelial cells in the G0 and G1 phases of cell cycle, and ultimately inhibits angiogenesis. TNFSF15 gene encodes three splice variants, namely VEGI-174, VEGI-251 and VEGI-192 depending on the number of amino acids included [26]. VEGI-251, also known as TL1A (TNF-like molecule 1A), is the longest one of the splice variants. The combination of TL1A and DR3 (Death Receptor 3) activates different signal transduction pathways by inducing NF-kB to activate initial T cell [10] and activating Caspases cascade to promote cell apoptosis [27]. These processes play an important role in the occurrence and development of tumors.

Till now, a few studies have been carried out to demonstrate the association of TNFSF15 polymorphisms with the susceptibility to cancer. In our previous study, we found that TNFSF15–638A > G polymorphism was associated with the development of gastric adenocarcinoma [20]. In another study, authors indicated that TNFSF15 rs6478106 is related to the risk of breast cancer in Chinese Han population [28]. In this study, we explored the association of TNFSF15 variants with the susceptibility to lung cancer and found that -638A > G and -358 T > C variants elevated the risk of SCLC, but not of NSCLC. These findings suggested that the TNFSF15 polymorphisms were involved in the development of various cancer types; however, the specific mechanism is not fully clear. We speculate that the TNFSF15 genetic variation affects the expression of TNFSF15 protein and then controls the downstream signal transduction molecules. These changes affect inflammatory and immune response, and further contribute to the development of cancers. Matijja and Clara found that an intron polymorphism of TNFSF15 (rs6478108) affected the expression level of TNFSF15 and increased NOD2-induced signaling and cytokines through caspase-8–induced IL-1 [29]. In our previous study, we found that the − 358 T > C polymorphism eliminates a nuclear factor Y (NF-Y) binding site and the -358C containing haplotypes had a significantly decreased reporter gene activity in gastric cells [20].

Tobacco smoking is recognized as one of the most important risk factors contributing to lung cancer [30]. Thus, we analyzed the effects of TNFSF15 variants on SCLC by smoking status. Studies have shown a strong association between tobacco exposure and the development of SCLC [31, 32]. Cigarette smoke contains many carcinogenic chemicals such as nicotine and carbon monoxide tar. The complexity of cigarette smoke makes the mechanisms of developing lung cancer even more complicated. At least, tobacco smoking potentially alters the tumor immune microenvironment by creating DNA damage and causing inflammatory response [33, 34]. TNFSF15 is closely related to the inflammatory response. It has been reported that TNFSF15 can directly induce proinflammatory cytokines [35]. Long-term exposure of DNA to the carcinogens in tobacco smoke will lead to a higher mutation load in SCLC [36]. Our present data showed that TNFSF15 -358 T > C polymorphism was related to SCLC among non-smokers instead of smokers, which needs more studies to explain. After stratified by smoking status, the sample size is not enough to evaluate the risk of this genetic variant with the risk of SCLC.

Age and gender are considered to be risk factors for tumor development and progression [37]. Our study showed the TNFSF15–638GG genotype elevated the risk of SCLC among males and individuals aged 60 years and older. Whether gender is related to the risk of lung cancer is controversial after taking into account smoking [38, 39, 40]. Due to the small size of several subgroups, a further larger-scale study needs to be conducted in order to carefully evaluate these findings.

In the future, it is necessary to evaluate the usability of these polymorphisms as a low-cost NSCLC screening tool for predicting individual lung cancer risk.

Conclusion

Taken together, our results indicated that TNFSF15 promoter polymorphisms might be involved in the development of SCLC.

Notes

Acknowledgments

The authors thank all patients and control subjects for their participation.

Funding

This work was supported by Foundation of Hebei high-level talents (A201400155 to X. Zhang) and Key Project of Natural Science Foundation of Hebei province of China (H2017209233 to X. Zhang). The funders were not involved in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

HG and ZN: acquisition, analysis, and interpretation of data; drafting the manuscript. ZZ and HW: data collection and analysis. YX, ZY, AL, ZJ: DNA extraction; acquisition and interpretation of data. XZ: design of the work, analysis and interpretation of data, revision of the article, final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All the study procedures were approved by the Ethics Committee of North China University of Science and Technology (2016134) and written informed consents were obtained from all participants of their own free will.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F: ; 2018.Google Scholar
  2. 2.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefGoogle Scholar
  3. 3.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80.CrossRefGoogle Scholar
  4. 4.
    de Groot P, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Radiol Clin N Am. 2012;50(5):863–76.CrossRefGoogle Scholar
  5. 5.
    Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008;99(8):1501–6.CrossRefGoogle Scholar
  6. 6.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.CrossRefPubMedGoogle Scholar
  7. 7.
    Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25(4):453–72.CrossRefGoogle Scholar
  8. 8.
    Grimaldo S, Tian F, Li LY. Sensitization of endothelial cells to VEGI-induced apoptosis by inhibiting the NF-kappaB pathway. Apoptosis : an international journal on programmed cell death. 2009;14(6):788–95.CrossRefGoogle Scholar
  9. 9.
    Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, Braun J, Targan SR. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008;135(2):552–67.CrossRefPubMedGoogle Scholar
  10. 10.
    Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16(3):479–92.CrossRefGoogle Scholar
  11. 11.
    Hou W, Medynski D, Wu S, Lin X, Li LY. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(15):5595–602.CrossRefGoogle Scholar
  12. 12.
    Cavallini C, Lovato O, Bertolaso A, Zoratti E, Malpeli G, Mimiola E, Tinelli M, Aprili F, Tecchio C, Perbellini O, et al. Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. Oncotarget. 2015;6(31):32061–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang N, Wu P, Shayiremu D, Wu L, Shan H, Ye L, Zhao X, Cai J, Jiang WG, Gong K, et al. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor. Int J Oncol. 2013;42(5):1664–73.CrossRefGoogle Scholar
  14. 14.
    Liang PH, Tian F, Lu Y, Duan B, Stolz DB, Li LY. Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis. 2011;14(1):61–8.CrossRefGoogle Scholar
  15. 15.
    Parr C, Gan CH, Watkins G, Jiang WG. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis. 2006;9(2):73–81.CrossRefGoogle Scholar
  16. 16.
    Meng Q, Wu S, Wang Y, Xu J, Sun H, Lu R, Gao N, Yang H, Li X, Tang B, et al. MPO promoter polymorphism rs2333227 enhances malignant phenotypes of colorectal Cancer by altering the binding affinity of AP-2alpha. Cancer Res. 2018;78(10):2760–9.CrossRefGoogle Scholar
  17. 17.
    Dimitrakopoulos FD, Antonacopoulou AG, Kottorou AE, Maroussi S, Panagopoulos N, Koukourikou I, Scopa C, Kalofonou M, Koutras A, Makatsoris T, et al. NF-kB2 genetic variations are significantly associated with non-small cell lung Cancer risk and overall survival. Sci Rep. 2018;8(1):5259.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen J, Jiang Y, Zhou J, Liu S, Gu Y, Jin G, Hu Z, Ma H, Shen H, Dai J: Genetic Variants in the Promoter Region of miR-10b and the Risk of Breast Cancer. 2017, 2017:2352874.Google Scholar
  19. 19.
    Capasso M, McDaniel LD, Cimmino F, Cirino A, Formicola D, Russell MR, Raman P, Cole KA, Diskin SJ. The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma. J Cell Mol Med. 2017;21(12):3224–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang Z, Yu D, Lu J, Zhai K, Cao L, Rao J, Liu Y, Zhang X, Guo Y. Functional genetic variants of TNFSF15 and their association with gastric adenocarcinoma: a case-control study. PLoS One. 2014;9(9):e108321.CrossRefPubMedGoogle Scholar
  21. 21.
    Pinsky PF, Zhu CS, Kramer BS: Lung cancer risk by years since quitting in 30+ pack year smokers. J Med Screen 2015, 22(3):0969141315579119.Google Scholar
  22. 22.
    Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol : official journal of the European Society for Medical Oncology. 2013;24(Suppl 6):vi99–105.CrossRefGoogle Scholar
  23. 23.
    Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(10):2244–55.CrossRefGoogle Scholar
  24. 24.
    Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, Zhou XA, Kaplan JB, Pro B, Choi J, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76.CrossRefGoogle Scholar
  25. 25.
    Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW. Phase I and Pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Med Oncol. 2010;21(2):376–81.CrossRefGoogle Scholar
  26. 26.
    Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res. 2001;89(12):1161–7.CrossRefGoogle Scholar
  27. 27.
    Bittner S, Knoll G, Fullsack S, Kurz M, Wajant H, Ehrenschwender M. Soluble TL1A is sufficient for activation of death receptor 3. FEBS J. 2016;283(2):323–36.CrossRefGoogle Scholar
  28. 28.
    Han S, Liu L, Xu F, Chen S, Yuan W, Fu Z, Li D, Li D. A case-control study about the association between vascular endothelial growth inhibitor gene polymorphisms and breast cancer risk in female patients in Northeast China. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2016;28(4):435–43.CrossRefPubMedGoogle Scholar
  29. 29.
    Hedl M, Abraham C. A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1. Proc Natl Acad Sci U S A. 2014;111(37):13451–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW Jr. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst. 1997;89(21):1580–6.CrossRefGoogle Scholar
  31. 31.
    Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(1):37–43.CrossRefGoogle Scholar
  32. 32.
    Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, Kris MG, Rekhtman N, Ladanyi M, Wang L, et al. Small-cell lung cancers in patients who never smoked cigarettes. J thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014;9(6):892–6.CrossRefGoogle Scholar
  33. 33.
    Desrichard A, Kuo F, Chowell D, Lee KW, Riaz N, Wong RJ, Chan TA, Morris LGT. Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas. J Natl Cancer Inst. 2018.Google Scholar
  34. 34.
    Rom O, Avezov K, Aizenbud D, Reznick AZ. Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol. 2013;187(1):5–10.CrossRefGoogle Scholar
  35. 35.
    Jin S, Chin J, Seeber S, Niewoehner J, Weiser B, Beaucamp N, Woods J, Murphy C, Fanning A, Shanahan F, et al. TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFalpha, from CD3+CD161+ T cells to exacerbate gut inflammation. Mucosal Immunol. 2013;6(5):886–99.CrossRefGoogle Scholar
  36. 36.
    Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463(7278):184–90.CrossRefGoogle Scholar
  37. 37.
    Patricia DG, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Radiol Clin N Am. 2012;50(5):863–76.CrossRefGoogle Scholar
  38. 38.
    Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology (Cambridge, Mass). 1992;3(1):61–4.CrossRefGoogle Scholar
  39. 39.
    Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88(3–4):183–92.CrossRefGoogle Scholar
  40. 40.
    Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011;20(8):1629–37.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.College of Life ScienceNorth China University of Science and TechnologyTangshanChina
  2. 2.School of Public HealthNorth China University of Science and TechnologyTangshanChina
  3. 3.Affliated Tangshan Gongren HospitalNorth China University of Science and TechnologyTangshanChina
  4. 4.School of Basic Medical SciencesNorth China University of Science and TechnologyTangshanChina

Personalised recommendations